FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Nashington,	D.C. 20549
-------------	------------

STATEMENT (	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_														
Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ ITCI ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Neumann Mark					1	maa Schalar Incraptes, Inc. [ 1101 ]								Director			10% Ov	vner	
						Date of Earliest Transaction (Month/Day/Year)							$\dashv$	X Officer below)	(give title		Other (s below)	pecify	
(Last) (First) (Middle)						08/07/2023								EVP, Chief Commercial Officer				er	
C/O INTRA-CELLULAR THERAPIES, INC.													E v 1, Giner Commercial Officer						
430 EAST 29TH STREET				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)							
					-									X Form filed by One Reporting Person					
(Street)														Form filed by More than One Reporting					
NEW YO	ORK N	Y	10016											Persor				9	
(City) (State) (Zip)					Ru	Rule 10b5-1(c) Transaction Indication													
					1_	Char	l thic	hov to inc	icate that s	tran	eaction was i	made nureu	ant to a con	tract, instructi	ion or writter	nlan t	that is intende	ad to	
					$  \sqcup $						ions of Rule				ion or writter	ι μιαιι ι	inal is interior	50 10	
		Tab	le I - No	on-Deriv	ative	Sec	curit	ties Ac	quired,	Dis	sposed o	of, or Be	neficial	ly Owned	d 				
1. Title of	Security (Ins	tr. 3)		2. Transa Date		on 2A. Deemed Execution Date,							es Acquired (A) or Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities		n: Direct	7. Nature of Indirect	
(Month/Day				ay/Year)	/Year) if any (Month/Day/Year)		Code (Instr.		,		Benefic	ially Following	(D) or Indirec (I) (Instr. 4)		Beneficial Ownership				
						(World Day Tear)		97				Reported		""		(Instr. 4)			
								Code	۱v	Amount	(A) or (D)	Price		ction(s) 3 and 4)					
					╆						- '	440.	<del>-  `</del>		-	_			
Common	Stock			08/07/	2023	023			M		55,300	) A \$18.5		9 100	100,639		D		
Common Stock 08/07/2			2023	.023		S		55,300	) D	\$58.79	(1) 45	,339		D					
		Т	able II	- Deriva	tive S	ecu	ıritie	es Acq	uired, [	Disp	osed of	, or Ben	eficially	Owned					
				(e.g., p	outs, c	alls	s, Wa	arrants	, optio	ns,	converti	ble sec	urities)						
1. Title of	2.	3. Transaction	3A. Deer		4.				6. Date Exercisable and 7. Title and			d	8. Price of	9. Numbe	9. Number of		11. Nature		
				Transac Code (li				Expiration Date Amount of (Month/Day/Year) Securities				Derivative Security	derivative Securities		Ownership Form:	of Indirect Beneficial			
					8)			Securities		(MOHIII/Day/ real)			Underlying		Beneficially		Direct (D)	Ownership	
	Derivative							uired				Derivative			Owned			(Instr. 4)	
	Security	ecurity						(A) or Disposed		(Instr. 3 and			nu 4)		Following (I) Reported	(I) (Instr. 4)			
						of (D)									Transaction	on(s)	1		
				(In:		tr. 3, 4 5)							(Instr. 4)						
				İ			İΠ						Amount	1			1		
													or Number						
									Date		Expiration		of						
					Code	٧	(A)	(D)	Exercisa	ble	Date	Title	Shares						
Stock Option												Common							
(right to buy)	\$18.59	08/07/2023			M			55,300	(2)		10/14/2028	Common Stock	55,300	\$0.00	0		D		

## Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$58.3319 to \$59.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

2. All shares underlying this option have vested.

## Remarks:

/s/ Lawrence J. Hineline, Attorney-in-fact 08/09/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.